The Incidence and Predictors of Developing Atrial Fibrillation in Patients With Inferior ST-segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Atrial fibrillation (AF) occurs in 5% to 18% of patient with acute ST-segment elevation myocardial infarctions (STEMIs) and 4.5% in patients with STEMI treated with percutaneous coronary intervention (PCI).
Diagnosis of AF in acute myocardial infarction (AMI) patients is important because it increases the risk of cardiovascular event and associated with increased in-hospital and long term rates . Atrial ischemia/infarction translates into P Q segment depression or elevation on the electrocardiogram and often associates with atrial tachyarrhythmias .
Side-branch obstruction is one of the adverse effects of PCI the location of the culprit vessel also affects the occurrence of AF in AMI Atrial arteries arise from the right coronary artery (RCA) and circumflex coronary artery (CX) and extend through the atrial myocardium to supply both chambers It is therefore conceivable that PCI of lesions located at the RCA and CX could lead to an accidental atrial branch occlusion .
Atrial myocardial ischemia secondary to atrial branches occlusion (ABO) might lead to mechanical atrial dysfunction, increased electrical vulnerability to atrial arrhythmias, and late structural remodeling .
The sino nodal (SN) artery originates from the proximal portion of the RCA in about 60% of humans Side branch occlusion of the SN artery occurring accidentally during PCI for proximal RCA lesions would provide an opportunity to produces SN dysfunction in humans. Uptill now , there have been no systematic studies concerning SN dysfunction caused by side-branch occlusion of the SN artery during PCI .
Left atrial volume seems to be a strong predictor of incident of AF , with increase in left atrial filling pressures, atrial stretch and enlargement of the chamber occur, leading to remodeling of the structure, physiologic properties, and electrical milieu of the left atrium, culminating in the development of AF
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Patients with inferior STEMI who will undergo PPCI (primary percutaneous coronary intervention )
Exclusion Criteria:
- -A history of preexisting AF
- Prior documentation of heart failure or reduced left ventricular ejection fraction < 50%,
- Severe valvular disease ( rheumatic , sclerotic ) or secondary to AMI
- Left ventricular hypertrophy : enlargement and thickening of the walls of the ventricle
- Patients with inferior STEMI treated with intravenous thrombolysis or conservative strategy
- Patients with inferior STEMI who undergo primary PCI and associated with right ventricular or posterior infarction
- History of pulmonary embolism or COPD ( chronic obstructive pulmonary disease )
- Those with thyrotoxicosis
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
incidence of atrial fibrillation in inferior STEMI patients after primary Percutaneous Coronary Intervention
Prazo: baseline
|
incidence of atrial fibrillation in inferior STEMI patients after primary Percutaneous Coronary Intervention
|
baseline
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
atrial branches occlusion and left atrial volume index as predictors of atrial fibrillation
Prazo: baseline
|
atrial branches occlusion and left atrial volume index as predictors of atrial fibrillation in inferior STEMI patients after primary Percutaneous Coronary Intervention
|
baseline
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Yehia Taha Kishk kishk, MD, Professor of cardiology department Assiut University
- Diretor de estudo: Mohamed Ali Mohamed Tohamy tohamy, MD, Lecturer of cardiology department Assiut University
Publicações e links úteis
Links úteis
- Clinical factors associated with the development of atrial fibrillation in the year following STEMI treated by primary PCI
- Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention
- Acute regional left atrial ischemia causes acceleration of atrial drivers during atrial fibrillation
- Atrial coronary artery occlusion during elective percutaneous coronary angioplasty
- Sinus arrest caused by occlusion of the sinus node artery during percutaneous coronary intervention for lesions of the proximal right coronary artery
- Left Atrial Volume: Important Risk Marker of Incident Atrial Fibrillation
- Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction
- Electrophysiological Effects of Selective Atrial Coronary Artery Occlusion in Humans
- Long Term Prognosis of Atrial Fibrillation in ST-Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention
- Left Atrial Size : Physiologic Determinants and Clinical Applications
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Antecipado)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- AF in inferior STEMI after PCI
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .